Furthermore, we have shown that rCCBE1 protein can facilitate the potential of angiogenesis and partially reduce the anti-tumor effects of imatinib to GIST cells, suggesting that CCBE1 might be used as a potential clinical therapy target for GIST. This evidence concerns the gene CCBE1 and gastrointestinal stromal tumor.